A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

Clinical trial NCT05596734 · COMPLETED

Trial details

NCT number: NCT05596734
Sponsor: BioNTech SE
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Influenza, Human COVID-19

Start date: 2022-10-28
Primary completion: 2023-12-28
Enrollment: 1019

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.